Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS May Clarify Drugs’ “Negotiated Price” To Address Cost Shifting In Part D

This article was originally published in The Pink Sheet Daily

Executive Summary

CMS acknowledges its current definition of negotiated prices for drugs could be interpreted as permitting Medicare Part D plans to overstate them, which may move beneficiaries more quickly to the coverage gap and beyond, when beneficiaries, the government and drug firms incur greater responsibility for costs.

You may also be interested in...



340B Dispute Resolution Process On Ice As Feuds Between Pharma, Providers, HHS Heat Up

Biden Administration’s regulatory freeze suspends HHS action to appoint an administrative dispute resolution board for the 340B program. Good news for manufacturers?

Medicare Part D Protected Classes Targeted in Last-Minute Payment Demo Update

If not reversed by the Biden Administration, demo program that puts plans at increased risk in catastrophic phase would also enhance negotiating leverage for drugs in the protected classes.

Biden Regulatory Freeze May Pause SUNSET Rule

Tactic aims to allow incoming Administration to scrutinize so-called ‘midnight rules’ issued in the final days of the Trump Administration before they take effect. Regulators may also solicit stakeholder comments on delayed rules.

Topics

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel